Tarlatamab with first-line chemo-immunotherapy for extensive-stage small cell lung cancer: DeLLphi-303 study
NCODA Oncology and Hematology Meeting Abstracts · 07.04.2026
DOI: 10.67209/xhrw2056 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 07.04.2026. Verfasst von Martin Wemke und 15 weiteren Autor:innen. Gefördert von: Amgen Inc..
Abstract (Originalsprache)
Tarlatamab with anti-PD-L1 achieved notable survival outcomes with manageable safety as maintenance therapy following 1L platinum-etoposide chemotherapy and anti-PD-L1 (1L chemo-IO) for extensive stage small cell lung cancer (ES-SCLC). In this phase 1b study (parts 2, 4, 7), the safety and efficacy of adding tarlatamab to 1L chemo-IO was assessed.
Förderung
- Amgen Inc.
Zitieren
APA
Wemke, M., Lau, S. C., Moskovitz, M., Demedts, I. K., Paulson, K. G., Swalduz, A., Waller, C. F., Paz-Ares, L., Nishio, M., Boyer, M., Yang, J. C., Parkes, A., Zhang, Y., Hamidi, A., Minocha, M., & Rocha, P. (2026). Tarlatamab with first-line chemo-immunotherapy for extensive-stage small cell lung cancer: DeLLphi-303 study. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/xhrw2056
Vancouver
Wemke M, Lau SC, Moskovitz M, Demedts IK, Paulson KG, Swalduz A, et al. Tarlatamab with first-line chemo-immunotherapy for extensive-stage small cell lung cancer: DeLLphi-303 study. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/xhrw2056
BibTeX
@article{Wemke2026,
author = {Wemke, Martin and Lau, Sally CM and Moskovitz, Mor and Demedts, Ingel KM and Paulson, Kelly G and Swalduz, Aurelie and Waller, Cornelius F and Paz-Ares, Luis and Nishio, Makato and Boyer, Michael and Yang, James CH and Parkes, Amada and Zhang, Yuyang and Hamidi, Ali and Minocha, Mukul and Rocha, Pedro},
title = {Tarlatamab with first-line chemo-immunotherapy for extensive-stage small cell lung cancer: DeLLphi-303 study},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/xhrw2056}
}
EUVIMED